CLINICAL RESEARCH STUDY
ROCHE Weight Loss Study
A Clinical Trial for Individuals with Obesity or Overweight Without Type 2 Diabetes
We are conducting a Phase 3 clinical research study evaluating the efficacy and safety of RO7795068, a dual GLP-1/GIP receptor agonist, for chronic weight management.
This study compares RO7795068 at different doses to a placebo, in conjunction with a reduced-calorie diet and increased physical activity.
Study overview
PURPOSE
To assess the efficacy and safety of RO7795068 for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity.
TOTAL PARTICIPATION TIME
Approximately 85 weeks
STUDY DESIGN
- Phase 3, randomized, double-blind, placebo-controlled, parallel group study
- 4 treatment groups — RO7795068 low, medium, or high dose, or placebo
- 76 weeks of treatment + 5 weeks of safety follow-up
- Visits approximately every 4 weeks
Who may qualify
- Age 18 or older
- Obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 and < 30 kg/m²) with at least 1 weight-related comorbidity
- Do not have Type 2 Diabetes
- Willing to adhere to dietary and physical activity counseling
- Meet additional study health criteria
Why Participate
- Close medical monitoring at no cost
- Regular assessments of body weight, anthropometric measurements, and metabolic parameters
- Contribution to research that may expand treatment options for weight management
COMPENSATION
Up to $3,500
For time and travel